RU2018102963A3 - - Google Patents

Download PDF

Info

Publication number
RU2018102963A3
RU2018102963A3 RU2018102963A RU2018102963A RU2018102963A3 RU 2018102963 A3 RU2018102963 A3 RU 2018102963A3 RU 2018102963 A RU2018102963 A RU 2018102963A RU 2018102963 A RU2018102963 A RU 2018102963A RU 2018102963 A3 RU2018102963 A3 RU 2018102963A3
Authority
RU
Russia
Application number
RU2018102963A
Other versions
RU2018102963A (ru
RU2734849C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018102963A publication Critical patent/RU2018102963A/ru
Publication of RU2018102963A3 publication Critical patent/RU2018102963A3/ru
Application granted granted Critical
Publication of RU2734849C2 publication Critical patent/RU2734849C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018102963A 2015-07-16 2016-07-15 Производные анилинпиримидина и их применения RU2734849C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510419018 2015-07-16
CN201510419018.X 2015-07-16
PCT/CN2016/090149 WO2017008761A1 (zh) 2015-07-16 2016-07-15 苯胺嘧啶衍生物及其用途

Publications (3)

Publication Number Publication Date
RU2018102963A RU2018102963A (ru) 2019-08-16
RU2018102963A3 true RU2018102963A3 (ru) 2019-12-24
RU2734849C2 RU2734849C2 (ru) 2020-10-23

Family

ID=57756722

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018102963A RU2734849C2 (ru) 2015-07-16 2016-07-15 Производные анилинпиримидина и их применения

Country Status (10)

Country Link
US (1) US10329277B2 (ru)
EP (1) EP3323817B1 (ru)
JP (1) JP6970081B2 (ru)
CN (1) CN107835811B (ru)
AU (1) AU2016292450B2 (ru)
CA (1) CA2992317A1 (ru)
HK (1) HK1250164A1 (ru)
RU (1) RU2734849C2 (ru)
TW (1) TWI739753B (ru)
WO (1) WO2017008761A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3205650T3 (pl) * 2014-10-11 2021-12-06 Shanghai Hansoh Biomedical Co., Ltd. Inhibitor EGFR i jego otrzymywanie i zastosowanie
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技(上海)有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
EP3399968B8 (en) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CN107540661A (zh) * 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 作为egfr抑制剂的苯胺嘧啶化合物的结晶
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
CN112174961A (zh) * 2019-07-04 2021-01-05 微境生物医药科技(上海)有限公司 一类抑制egfr激酶的化合物及其制备方法和用途
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
CA2778265A1 (en) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
RU2012120784A (ru) * 2009-11-12 2013-12-20 Селвита С.А. Соединение, способ его получения, фармацевтическая композиция, применение соединения, способ модулирования или регулирования сериновых/треониновых киназ и средство, модулирующее сериновые/треониновые киназы
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
ES2900230T3 (es) * 2011-07-27 2022-03-16 Astrazeneca Ab Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
CN104761544B (zh) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN105085489B (zh) * 2014-11-05 2019-03-01 益方生物科技(上海)有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106117185B (zh) * 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用

Also Published As

Publication number Publication date
RU2018102963A (ru) 2019-08-16
HK1250164A1 (zh) 2018-11-30
CN107835811B (zh) 2019-11-08
TW201703768A (zh) 2017-02-01
JP6970081B2 (ja) 2021-11-24
CA2992317A1 (en) 2017-01-19
CN107835811A (zh) 2018-03-23
US20180208581A1 (en) 2018-07-26
EP3323817B1 (en) 2022-10-19
KR20180030190A (ko) 2018-03-21
EP3323817A1 (en) 2018-05-23
AU2016292450B2 (en) 2021-03-25
JP2018520190A (ja) 2018-07-26
WO2017008761A1 (zh) 2017-01-19
EP3323817A4 (en) 2019-04-10
TWI739753B (zh) 2021-09-21
US10329277B2 (en) 2019-06-25
RU2734849C2 (ru) 2020-10-23
AU2016292450A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
BR112018004878A2 (ru)
RU2018102963A3 (ru)
BR112018005680A2 (ru)
BE2015C047I2 (ru)
BE2015C044I2 (ru)
BR0002033B1 (ru)
BR0009182B1 (ru)
BR0002874B1 (ru)
BR0317646B1 (ru)
BR0002694B1 (ru)
BR0002435B1 (ru)
BR0002402B1 (ru)
CN303069340S (ru)
BR0001810B1 (ru)
BR0001684B1 (ru)
CN303108724S (ru)
BR0003928B1 (ru)
CN303108723S (ru)
CN303107599S (ru)
CN303100280S (ru)
CN303095693S (ru)
CN303089741S (ru)
BR0000695B1 (ru)
CN303070894S (ru)
BR0003751B1 (ru)